[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370563-105":59,"doc-detail-370563-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sustainability-based-comparative-stability-of-oxaliplatin-plus-leucovorin-and-5-fluorouracil-in-infusion-bags-hplc-dad-stability-study","Sustainability-based comparative stability of oxaliplatin plus leucovorin and 5-fluorouracil in infusion bags - HPLC-DAD stability study","","Sustainability-based stability of oxaliplatin (OXA) plus leucovorin (LV) and 5-fluorouracil (5-FU) was evaluated in infusion bags containing either 5% dextrose or normal saline, with comparison to the corresponding single-drug solutions. An HPLC diode-array detection method was developed and validated for simultaneous quantification. Stability was assessed at room temperature and refrigeration over two weeks. Mixtures showed chemical degradation of OXA under some conditions, while LV exhibited relatively better stability in saline. 5-FU remained relatively stable in both diluents and temperatures. The validated method was applied to plasma and colonic media samples, and method greenness and related metrics were investigated.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sustainability-based-comparative-stability-of-oxaliplatin-plus-leucovorin-and-5-fluorouracil-in-infusion-bags-hplc-dad-stability-study/370563/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sustainability-based-comparative-stability-of-oxaliplatin-plus-leucovorin-and-5-fluorouracil-in-infusion-bags-hplc-dad-stability-study/370563.png","ImageObject",300,407,{"name":92,"@type":93},"Alex Sinclair","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of the study?","Question",{"text":112,"@type":113},"To determine the stability of OXA/LV binary mixtures in infusion bags containing either 5% dextrose or normal saline, compared with single solutions including 5-FU, under room temperature and refrigeration.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was drug stability measured?",{"text":117,"@type":113},"An HPLC diode-array detection method was developed, validated, and used to simultaneously determine OXA, LV, and 5-FU.",{"name":119,"@type":110,"acceptedAnswer":120},"Which drugs showed degradation or better stability under the tested conditions?",{"text":121,"@type":113},"In 5% dextrose, OXA in OXA/LV mixtures showed chemical degradation at room temperature, while refrigerated solutions were more stable. In normal saline, LV showed relative stability across 15 days with marked degradation of OXA. 5-FU remained relatively stable in both diluents at both temperatures.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370563,1790377995,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099523882182,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nSustainability-based comparative stability of oxaliplatin plus leucovorin and 5-fluorouracil in infusion bags with application to plasma and colonic media samples  \nHadir M. Maher􀀍, Salma Mahmoud Mohamed, Ekram M. Hassan & Amira Fawzy El-Yazbi  \nFOLFOX is widely used in the treatment of colon cancer. The combination of oxaliplatin (OXA), 5-fluorouracil (5-FU), and leucovorin (LV) is administrated according to strict protocols. Based on incompatibility studies, LV and OXA are supplied concurrently via intravenous infusion, followed by intravenous administration of 5-FU. This study aims at determining the stability of the binary mixture ofOXA and LV diluted in infusion bags containing either 5% dextrose or normal saline compared with their single solutions besides single solutions of 5-FU at two temperatures (room temperature and refrigeration) for two weeks. HPLC diode array detection method was developed and validated to simultaneously determine the three drugs. Stability studies in 5% dextrose solution revealed that mixtures ofOXA and LV kept at room temperature showed chemical degradation for OXA, with better stability for refrigerated solutions. Generally, single solutions showed considerable stability. Using normal saline, a combination ofOXA/LV showed relative stability of LV over the 15 days of study with marked degradation ofOXA. 5-FU was relatively stable in 5% dextrose and normal saline at both temperatures. Method’s applicability was extended to the determination of the cited drugs in plasma and colonic media samples. Method’s sustainability, blueness, and whiteness were investigated.  \nKeywords HPLC-DAD, FOLFOX, Stability, Infusion bags, Normal saline, 5% dextrose, Greenness, Blueness, Whiteness  \nColon cancer (CC) is the third most frequent malignancy and is the second major cause of cancer mortality globally. Lymph node invasion is a prominent prognostic factor in localized CC, with 5-year overall survival (OS) rates of 99% and 70% for patients with stage I and II CC, respectively, versus just 45 to 65% for stage III patients, who account for around 35% of CC at diagnosis1. Management protocols for CC usually rely on treatments including surgery, chemotherapy, radiation therapy, and targeted therapy. Selection of a particular plan is based on a number of variables, such as the cancer’s stage, potential side effects, the patient’s preferences, and general health2.  \nSince the late 1980s, adjuvant chemotherapies have become more significant for various stages of cancer and are administered in accordance with conventional clinical criteria3. The treatment of CC has involved the use of five different regimens: FOLFIRI (5-fluorouracil (5-FU), leucovorin(LV), and irinotecan); FOLFOXIRI (LV, 5-FU, oxaliplatin (OXA), and irinotecan); Cape-Ox (capecitabine and OXA); FOLFOX (5-FU, LV, and OXA); besides combination therapy of 5-FU and LV. Yet the serious side effects including severe diarrhea with the use ofFOLFIRI, FOLFOXIRI4, and hand-foot syndrome with severe nausea/vomiting generated from capecitabinein Cape-Ox contributed to their current limited use5. Since the early 1990s, the protocols which have been continued to be commonly employed for the treatment ofCC are FOLFOX and 5-FU/ LV binary combinations6. In 2004,the MOSAIC ( Multi Omic Spatial Atlas in Cancer) research established the FOLFOX regimen as a standard treatment for stage III CC4,7. The inclusion of OXA to the doublet combination of 5-FU/LV leads to a considerable improvement in response, with an extension of progression-free survival (PFS) and overall survival (OS)8,9. Nowadays, FOLFOX is commonly used as adjuvant therapy for patients with high risk of recurrence (stages II and III) of primary CC or metastatic colorectal cancer. However, it is noteworthy to mention that  \nPharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, University of Alexandria, Elmessalah 21","cbCaidTpyAzF26Z7","https://ap.wps.com/l/cbCaidTpyAzF26Z7","pdf",4874434,"English","# Stability study design\n## Formulations and storage conditions\n## Analytical method development and validation\n# Results and comparative stability findings\n## Effects in 5% dextrose\n## Effects in normal saline\n# Applications and sustainability assessment\n## Plasma and colonic media sample analysis\n## Method sustainability and greenness metrics","[{\"question\":\"What was the main goal of the study?\",\"answer\":\"To determine the stability of OXA/LV binary mixtures in infusion bags containing either 5% dextrose or normal saline, compared with single solutions including 5-FU, under room temperature and refrigeration.\"},{\"question\":\"How was drug stability measured?\",\"answer\":\"An HPLC diode-array detection method was developed, validated, and used to simultaneously determine OXA, LV, and 5-FU.\"},{\"question\":\"Which drugs showed degradation or better stability under the tested conditions?\",\"answer\":\"In 5% dextrose, OXA in OXA/LV mixtures showed chemical degradation at room temperature, while refrigerated solutions were more stable. In normal saline, LV showed relative stability across 15 days with marked degradation of OXA. 5-FU remained relatively stable in both diluents at both temperatures.\"}]","Sustainability-based comparative stability of oxaliplatin plus leucovorin and 5-fluorouracil in infusion bags - HPLC-DAD stability study | PDF",1790189181,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83f6f072bf234203deeadee17a208915.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5f7ae802e0fb7ffc9ccf4530b764b2d9.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b443d3c2e0025271b60ba17b104aa838.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28eafdb256e4ca947c752ef33c7acb40.webp",980,1287]